Get the Stockscreener App
2.04
6.81%
0.13
Pre-market:
1.99
-0.05
-2.45%
Serina Therapeutics Inc stock is traded at $2.04, with a volume of 141.70K.
It is up +6.81% in the last 24 hours and up +24.39% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.91
Open:
$1.86
24h Volume:
141.70K
Relative Volume:
0.05
Market Cap:
$30.59M
Revenue:
$130.00K
Net Income/Loss:
$-21.29M
P/E Ratio:
-1.0319
EPS:
-1.977
Net Cash Flow:
$-18.29M
1W Performance:
+15.25%
1M Performance:
+24.39%
6M Performance:
-30.14%
1Y Performance:
-64.58%
1-Day Range:
$1.835
$2.10
1-Week Range:
$1.71
$2.10
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.04 | 28.65M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Insider Buying: Karen Wilson Acquires Shares of Serina Therapeutics Inc (SER) - GuruFocus
Serina Therapeutics director Karen Wilson buys $17,749 common stock By Investing.com - Investing.com India
Serina Therapeutics director Karen Wilson buys $17,749 common stock - Investing.com UK
Director Karen J. Wilson boosts Serina (SER) stake with 10,100-share purchase - Stock Titan
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Losses Wider Than Expected as Pre-Revenue Biotech Continues Clinical DevelopmentFinal Results - newsline.com
Serina Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Serina Therapeutics (SER) Stock Price, News & Analysis $SER - MarketBeat
Serina Therapeutics (SER) Gains 4% as It Tests Key Resistance at $1.90BPI Bull Confirmed - newsline.com
Serina Therapeutics (SER) Tests Key Support After Modest DeclineDealer Delta - newsline.com
SER Q1 2026 Earnings: EPS Misses Estimates as Development-Focused Biotechnology Firm Continues Pipeline ProgressEarnings Revision Upgrade - newsline.com
SER News | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
[EFFECT] Serina Therapeutics, Inc. SEC Filing - Stock Titan
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Company Reports Wider Loss - thelegaladvocate.com
Serina Therapeutics Inc. Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates Development CostsEarnings Volatility Report - The Legal Advocate
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Serina Therapeutics (SER) grants CEO 10,100 common shares - Stock Titan
Serina Therapeutics (SER) SVP granted 85,558 stock options at $1.89 - Stock Titan
Serina Therapeutics (SER) CEO awarded 380,825 stock options - Stock Titan
Serina Therapeutics (SER) CFO awarded 123,019 stock options at $1.89 - Stock Titan
Serina Therapeutics (SER) CSO receives 85,558 stock options at $1.89 strike - Stock Titan
Serina Therapeutics (SER) Faces Headwinds: Shares Decline 3% Toward Support at $1.82Break of Structure - The Legal Advocate
Serina Therapeutics director Karen Wilson buys $37,000 in shares By Investing.com - Investing.com India
Serina Therapeutics director Karen Wilson buys $37,000 in shares - Investing.com
Director boosts stake in Serina Therapeutics (SER) with 20K-share buy - Stock Titan
Serina Therapeutics (SER) Faces Selling Pressure, Tests Key Support LevelsMAMA Signal - thelegaladvocate.com
Serina Therapeutics (SER) Slips 6% as Stock Approaches Key Support LevelGap Down Bounce Plays - thelegaladvocate.com
Serina Therapeutics Inc (SER) Q1 2026 Earnings: EPS Miss Amid Continued Development ProgressFinancial Summary - Newser
Serina Therapeutics Q1 2026 Earnings: EPS Misses Estimates as Stock Climbs Despite LossGAAP Earnings Report - Newser
Serina Therapeutics Inc. (SER) Recovers 4.93% as Stock Approaches Key Resistance at $2.08Volume Spike Alerts - Newser
Serina Therapeutics Inc. (SER) Gains Nearly 5% as Stock Approaches Key ResistanceTop Analyst Buy Signals - Newser
Director at Serina Therapeutics (SER) makes open-market buy of 12,183 shares - Stock Titan
16.45M Serina shares registered for resale (NYSE: SER) - Stock Titan
Serina Therapeutics : Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi - marketscreener.com
SER Stock Price, Quote & Chart | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
Serina Therapeutics (SER) Gets a Buy from JonesTrading - The Globe and Mail
Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks - The Globe and Mail
Serina Therapeutics 1Q Loss/Shr 58c >SER - Moomoo
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parkinson's drug trial moves ahead as Serina adds $21.2M funding - Stock Titan
Serina Therapeutics (NYSE: SER) raises $21.2M and advances SER-252 trial - Stock Titan
Serina Therapeutics (NYSE: SER) posts Q1 loss and raises $21.2M PIPE amid cash risk - Stock Titan
SER Technical Analysis | Trend, Signals & Chart Patterns | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Cap:
|
Volume (24h):